Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom general practice research database

Haematologica

Volumn 95, Issue 7, 2010, Pages 1167-1175

  Sarpatwari, Ameet ^a,b   Bennett, Dimitri ^c   Logie, John W ^d   Shukla, Amit ^c   Beach, Kathleen J ^c   Newland, Adrian C ^b   Sanderson, Simon ^a   Provan, Drew ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

General practice research database; Primary immune thrombocytopenia; Thromboembolic events

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; CONTROLLED STUDY; DATA BASE; FEMALE; FOLLOW UP; GENERAL PRACTICE; HIGH RISK PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PREVALENCE; PRIMARY IMMUNE THROMBOCYTOPENIA; RISK ASSESSMENT; THROMBOCYTOPENIA; THROMBOEMBOLISM; UNITED KINGDOM; VEIN THROMBOSIS; COMPLICATION; DISEASE PREDISPOSITION; FACTUAL DATABASE; IMMUNOLOGY; RISK;

ADULT; DATABASES, FACTUAL; DISEASE SUSCEPTIBILITY; HUMANS; INCIDENCE; RISK; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 77954530191     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.018390     Document Type: Article

References (29)

1. Chang M, Nakagawa PA, Williams SA, Schwartz MR, Imfeld KL, Buzby JS, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood. 2003;102(3):887-895.
2. McMillan R, Nugent D. The effect of antiplatelet autoantibodies on megakaryocytopoiesis. Int J Hematol. 2005;81(2):94-109.
3. McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004;103(4):1364-1379.
4. Gernsheimer T, Stratton J, Ballem PJ, Slichter SJ. Mechanisms of response to treatment in autoimmune thrombocytopenic purpura. N Engl J Med. 1989; 320(15):974-980.
5. Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JW, Slichter SJ. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest. 1987;80(l):33-40.
6. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88(l):3-40.
7. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003;120(4):574-596.
8. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol. 1997;84(3):223-243.
9. Neylon AJ, Saunders PW, Howard MR, Proctor SJ, Taylor PR. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol. 2003;122(6):966-974.
10. Schoonen WM, Kucera G, Coalson J, Li L, Rutstein M, Mowat F, et al. Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database. Br J Haematol. 2009;145(2):235-244.
11. Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost. 2006;4(11): 2377-2383.
12. Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood. 1999; 94(3):909-913.
13. Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001;97(9): 2549-2554.
14. George JN. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med. 2006;354(18):1927-1935.
15. Ruiz-Irastorza G, Khamashta MA, Castellino G, Hughes GR. Systemic lupus erythematosus. Lancet. 2001;357(9261): 1027-1032.
16. Aledort LM, Hay ward CP, Chen MG, Nichol JL, Bussel J. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thromb op oietin, and circulating antithrom-bopoietin antibodies. Am J Hematol. 2004;76(3):205-213.
17. Bennett D, Forssen U, Enger C, Nelson J. Risk of thromboembolic events (TE) among patients with chronic Idiopathic Thrombocytopenic Purpura (ITP). Haematologica. 2008;93(Supplement 1).
18. Garcia Rodriguez LA, Perez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol. 1998;45(5):419-425.
19. Edwards CJ, Arden NK, Fisher D, Saperia JC, Reading I, Van Staa TP, et al. The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database. Rheumatology (Oxford). 2005;44(ll):1394-1408.
20. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ. 1991;302(6779): 766-778.
21. Soriano JB, Maier WC, Visick G, Pride NB. Validation of general practitioner-diagnosed COPD in the UK General Practice Research Database. Eur J Epidemiol. 2001;17(12):1075-1080.
22. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(ll):2386-2393.
23. Thomas SL, Edwards CJ, Smeeth L, Cooper C, Hall AJ. How accurate are diagnoses for rheumatoid arthritis and juvenile idiopathic arthritis in the general practice research database¿ Arthritis Rheum. 2008;59(9): 1314-1321.
24. Lawrenson R, Todd JC, Leydon GM, Williams TJ, Farmer RD. Validation of the diagnosis of venous thromboembolism in general practice database studies. Br J Clin Pharmacol. 2000;49(6):591-606.
25. Heit JA. The epidemiology of venous thromboembolism in the community: implications for prevention and management. J Thromb Thrombolysis. 2006;21(1): 23-39.
26. Kearon C. Epidemiology of venous thromboembolism. Semin Vasc Med. 2001;1(1):7-26.
27. Bidot CJ, Jy W, Horstman LL, Ahn ER, Yaniz M, Ahn YS. Antiphospholipid antibodies (APLA) in immune thrombocytopenic purpura (ITP) and antiphospholipid syndrome (APS). Am J Hematol. 2006;81(6):391-406.
28. Atsumi T, Furukawa S, Amengual O, Koike T. Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis. Lupus. 2005;14(7):499-504.
29. Diz-Kucukkaya R, Hacihanefioglu A, Yenerel M, Turgut M, Keskin H, Nalcaci M, et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood. 2001;98(6):1760-1774.